Mounjaro and Cardiovascular Disease: What the FDA Says
The US FDA has approved Eli Lilly's Mounjaro (tirzepatide) to cut the risk of major cardiovascular events in adults with type 2 diabetes at high risk of heart problems. Here's what the decision means, what the evidence shows, and what it means for UK patients.
Mounjaro and Cardiovascular Disease: What the FDA's New Approval Means
The US Food and Drug Administration (FDA) has approved Mounjaro (tirzepatide) for a new use, specifically to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and at a higher risk of heart problems.
The approval covers the risk of cardiovascular death, non-fatal heart attack and non-fatal stroke, a group of outcomes doctors often shorten to “MACE” [1][2].
Mounjaro is already established as a treatment path for type 2 diabetes and weight management. This recent decision by the FDA is significant as it recognises the medicine not only in the management of blood sugar and weight but also in protecting heart health of those living with diabetes and cardiovascular disease [1,3].
What the FDA has approved
The new indication applies specifically to adults with type 2 diabetes who are at high risk of cardiovascular events, for example people who already have established heart or blood vessel disease.
Note: It is not a licence to use the medicine purely for heart protection in people without diabetes, and it does not change how Mounjaro is used for blood sugar control or weight management [1][2].
The approval was granted by the FDA, which is the medicines regulator in the United States. It follows a large clinical trial designed to test whether tirzepatide is safe for the heart and whether it offers cardiovascular benefit [1][3].
The evidence: the SURPASS-CVOT trial
The FDA’s decision was based on the SURPASS-CVOT trial, one of the largest cardiovascular outcome trials of its kind. The study involved [3][4]:
- 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease
- Recruitment across 640 sites in 30 countries
- Participants aged around 64 years old on average
- Roughly three in ten participants were women
Importantly, the trial did not compare tirzepatide against a dummy treatment (a placebo). Instead, it compared it head-to-head against dulaglutide (Trulicity), another injectable diabetes medicine that already has proven cardiovascular benefit. Participants were followed for a median of around four years [3][4].
What the results showed
Serious heart problems, like heart attacks and strokes, happened in 12.2% of people taking tirzepatide and in 13.1% of people taking dulaglutide. So slightly fewer people on tirzepatide had these events, about 8% fewer. But the gap between the two groups was small, so some of that difference could just be down to luck rather than the drug itself. The safest thing to say is that tirzepatide is at least as good for the heart as dulaglutide, not that it is clearly better [1][3].
That is a reassuring finding, because dulaglutide is a well-established treatment. People taking tirzepatide also lost noticeably more weight (about 11.6% of their body weight, compared with 4.5%) and had better blood sugar control [3][4].
In short, tirzepatide guards the heart at least as well as a trusted existing treatment, while doing more for weight and blood sugar [3][4].
A view from our Superintendent Pharmacist:
“This approval is encouraging news for people managing type 2 diabetes, because it recognises that a medicine many patients already know can also help protect the heart.
It is important to keep it in context, though. This is a decision by the US regulator, it applies to people who already have diabetes and are at high cardiovascular risk, and it is not a reason to start or change any medication on your own.
If you have type 2 diabetes and you are worried about your heart health, the best step is to speak to your GP, diabetes team or pharmacist, who can look at your individual situation.”
- Umar Razzaq, Clinical Pharmacist at Pharmacy Online
What this means for patients in the UK
It is worth being clear that this is a US regulatory decision. In the UK, Mounjaro is licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for type 2 diabetes and for weight management, and it remains a prescription-only medicine. The FDA approval does not by itself change the UK licence or how the medicine can be prescribed here [5][6].
That said, the SURPASS-CVOT trial adds to the growing body of evidence about how these medicines affect the heart, and UK regulators and clinical guideline groups review this kind of data over time. Anyone taking Mounjaro should continue as prescribed and should never stop, start or adjust their treatment without speaking to a healthcare professional first [5][6].
Safety and side effects
As with earlier studies, the most common side effects in the trial were gastrointestinal, including nausea, diarrhoea, vomiting, constipation, indigestion and reduced appetite. These were generally mild to moderate and tended to occur while the dose was being increased.
More serious but less common risks associated with this class of medicine include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar, dehydration and allergic reactions. Your prescriber will weigh these risks against the benefits for you [1][2].
The bottom line
The FDA's decision is a meaningful step that formally recognises Mounjaro's cardiovascular benefit for a specific group of people with type 2 diabetes. For UK patients, the practical advice has not changed: keep taking any medication as prescribed, attend your regular reviews, and talk to your GP, diabetes team or pharmacist if you have questions about your treatment or your heart health [1][5].
This article is for general information and is not a substitute for advice from a qualified healthcare professional. Mounjaro is a prescription-only medicine. Always speak to your GP, diabetes team or pharmacist before making any decision about your treatment.
References
- Eli Lilly and Company. FDA approves Lilly’s Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. Press release, 28 August 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjaro-tirzepatide-reduce-cardiovascular
- US Food and Drug Administration. Mounjaro (tirzepatide) prescribing information. FDA, 2026. https://www.fda.gov/media/191437/download
- SURPASS-CVOT Investigators. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. New England Journal of Medicine, 2026. doi:10.1056/NEJMoa2505928. https://www.nejm.org/doi/full/10.1056/NEJMoa2505928
- American College of Cardiology. SURPASS-CVOT: Is Tirzepatide Superior to Dulaglutide in PatientsWith T2D and ASCVD? ACC.org, January 2026. https://www.acc.org/latest-in-cardiology/journal-scans/2026/01/07/14/20/surpass-cvot
- Diabetes UK. Mounjaro: uses, how it works and side effects. Diabetes UK, accessed September 2026. https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/tablets-and-medication/glp-1/mounjaro
- Medicines and Healthcare products Regulatory Agency. MHRA authorises Mounjaro for weight management. Reported via European Pharmaceutical Review, accessed September 2026. https://www.europeanpharmaceuticalreview.com/news/189881/mhra-authorises-mounjaro-for-weight-management/
You might also like
Weight Loss Jabs: Know the Warning Signs and Avoid Unregulated Online Sellers
We respond to reports that hundreds of suspected deaths and thousands of severe adverse reactions possibly linked to GLP-1 weight-loss injections have been logged with the UK medicines regulator, and calls for patients to use only properly regulated, prescription-based services.
What to Expect From Our Online Weight Loss Service
Thinking about using our online weight loss service? Find out what happens at each stage, from first consultation through to ongoing check-ins and support.
Is Mounjaro Safe? UK Safety Guide 2026
Mounjaro is safe for most adults, as long as it's prescribed by a professional and used under medical supervision. However, there are some serious side effects.